ClinicalTrials.gg
CompletedNCT06921759ADtouchUpdated Aug 20, 2026

A Study to Investigate the Efficacy and Safety of Lebrikizumab in Participants With Moderate-to-Severe Atopic Hand and Foot Dermatitis

A Phase 3 interventional study of Lebrikizumab and Placebo in Atopic Hand and Foot Dermatitis, sponsored by Eli Lilly and Company. Completed at 76 sites in 8 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-08-20.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
221
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Study summary

The main purpose of this study is to assess the efficacy of lebrikizumab versus placebo on skin lesions in adults and adolescent participants with atopic hand and foot dermatitis.

This study lasts up to 32 weeks, including a 6-week screening period, a 16-week treatment period, and a safety follow-up visit 12 weeks after the last dose.

02

Conditions studied

  • Atopic Hand and Foot Dermatitis
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have an unequivocal diagnosis of chronic atopic hand and/or foot dermatitis at least 1 year prior to screening, regardless of the extent and severity of concomitant atopic dermatitis (AD) on other areas of the body. AD must be present in at least 2 of the 4 mentioned anatomical areas: left hand, right hand, left foot, or right foot at screening and baseline.
  • Have a Hand Foot - Investigator Global Assessment (HF-IGA) score of 3 or 4 at the screening and baseline visits.
  • Have a baseline hand and foot peak pruritus (numeric rating scale) NRS score ≥4.
  • Have a documented history by the investigator of inadequate response to topical medication(s) (topical (TCIs/TCS), topical PDE-4 inhibitors, or topical janus kinase (JAK) inhibitors) in the treatment of atopic hand foot dermatitis (AHFD) within 6 months of screening, or use of topical medications is medically inadvisable (due to intolerance to treatment, reactions, significant skin atrophy of hand and feet, and systemic effects, as assessed by the investigator or by the treating physician of the participant).
  • For adolescent participants, body weight ≥40 kilograms (kg) at baseline.

Exclusion criteria

Exclusion Criteria:

  • Have a positive patch test reaction to 1 or more allergens (a score of 1+ or above according to the International Contact Dermatitis Research Group grading scale) before baseline AND which are deemed to be in the view of the investigator as the current cause of the hand and foot dermatitis.
  • Have a documented diagnosis of allergic contact dermatitis (ACD) of hands and/or feet, and have a positive patch test reaction at screening, regardless of whether the history of current skin exposure to products containing this allergen (current relevance) is present.
  • Have a documented or strong clinical suspicion of the diagnosis of protein contact dermatitis of hands and/or feet. These are the participants with occupational or nonoccupational contact with proteins such as food, latex, and so on, who have positive prick test results and present with lesions of contact urticaria or dermatitis on hands and feet.
  • Have a documented exposure to irritants in the occupational or non-occupational (household/recreational) setting that is believed to be a predominant cause of the current hand and foot dermatitis as per the judgment of the investigator.
  • Presence of skin comorbidities on hand and/or foot that may interfere with study assessments, such as (but not limited to) palmoplantar psoriasis, palmoplantar keratoderma, impetiginized eczema, lichen planus, pityriasis rubra pilaris, herpes simplex, erythema multiforme, tinea, or scabies.
  • Have skin comorbidities that may interfere with study assessments.
  • Treatment with topical medications on the hands and feet within 2 weeks before the baseline visit (except for the use of the participant's own emollients).
  • Prior treatment with interleukin-13 (IL-13) inhibitors such as lebrikizumab or tralokinumab.
  • Have received any within less than 4 weeks of the baseline visit or intend to receive a live attenuated vaccine during the study, or within 4 weeks after receiving the last dose of study intervention.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
221 participants (actual)

Study arms

  • Experimental
    Lebrikizumab

    Lebrikizumab administered subcutaneously (SC).

    Drug: Lebrikizumab

  • Placebo comparator
    Placebo

    Placebo Administered SC.

    Drug: Placebo

Interventions

  • Administered SC

    Also known as: LY3650150

  • DrugPlacebo

    Administered SC

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving a Hand and Foot Investigator Global Assessment (HF-IGA) Score of 0 or 1 with ≥2-point Improvement from Baseline

    The HF-IGA is an assessment scale used to determine the severity of hand and foot atopic dermatitis (AD) and clinical response to treatment on a 5-point scale, 0 (clear) to 4 (severe). Higher scores indicate more disease severity.

    Time frame: Week 16

Secondary outcomes

  1. Percentage of Participants with a HF-Peak Pruritus Numeric Rating Score (NRS) of ≥4 points at Baseline Who Achieve a ≥4-point Reduction (Improvement) from Baseline

    The HF-peak pruritus NRS scale is an assessment tool used daily by the participants to rate their worst hand and feet itch intensity on a scale ranging from 0 (no itch) to 10 (worst imaginable itch).

    Time frame: Week 16

  2. Percentage of Participants with a HF-Peak Pruritus Numeric Rating Score (NRS) of ≥4 points at Baseline Who Achieve a ≥4-point Reduction (Improvement) from Baseline

    The HF-peak pruritus NRS scale is an assessment tool used daily by the participants to rate their worst hand and feet itch intensity on a scale ranging from 0 (no itch) to 10 (worst imaginable itch).

    Time frame: Week 2

  3. Percentage of Participants with HF-Peak Pruritus NRS of ≥4 points at Baseline Who Achieve a ≥4-point Reduction (Improvement) from Baseline

    The HF-peak pruritus NRS scale is an assessment tool used daily by the participants to rate their worst hand and feet itch intensity on a scale ranging from 0 (no itch) to 10 (worst imaginable itch).

    Time frame: Baseline, Week 4

  4. Percentage of Participants with a HF-Peak Pain NRS of ≥4 points at Baseline Who Achieve a ≥4-point Reduction (Improvement) from Baseline

    The HF-peak pain NRS Scale is an assessment tool used daily by the participants to report the intensity of pain. Participants select the number between 0 and 10 that best fits their worst pain intensity over the past 24 hours (0 = no pain and 10 = the worst pain possible).

    Time frame: Week 16

  5. Percentage of Participants Achieving a Hand and Foot Investigator Global Assessment (HF-IGA) Score of 0 or 1 with ≥2-point Improvement from Baseline

    The HF-IGA is an assessment scale used to determine the severity of hand and foot atopic dermatitis (AD) and clinical response to treatment on a 5-point scale, 0 (clear) to 4 (severe). Higher scores indicate more disease severity.

    Time frame: Week 4

  6. Percentage of Participants Achieving a Hand and Foot Investigator Global Assessment (HF-IGA) Score of 0 or 1 with ≥2-point Improvement from Baseline

    The HF-IGA is an assessment scale used to determine the severity of hand and foot atopic dermatitis (AD) and clinical response to treatment on a 5-point scale, 0 (clear) to 4 (severe). Higher scores indicate more disease severity.

    Time frame: Week 8

  7. Percentage of Participants Who Are "Satisfied" or "Very Satisfied" on Atopic Hand Dermatitis Clearance Satisfaction (AHDCS)

    This single-item question assesses participants' satisfaction with hand clearance at the current time. The response options are reported as the percentage of participants who selected 1 of the following: Very Satisfied, Satisfied, Neither Satisfied nor Dissatisfied, Dissatisfied, or Very Dissatisfied.

    Time frame: Week 16

  8. Percent Change from Baseline in Hand and Foot Peak Pain NRS

    The HF-peak pain NRS Scale is an assessment tool used daily by the participants to report the intensity of pain. Participants select the number between 0 and 10 that best fits their worst pain intensity over the past 24 hours (0 = no pain and 10 = the worst pain possible).

    Time frame: Baseline, Week 16

  9. Percent Change from Baseline in Modified Total Lesion Symptom Scale (mTLSS) for Hand and Foot Lesions

    The mTLSS is an investigator-reported scale that combines the evaluation of lesion severity of hand eczema (HE) (erythema, edema, desquamation, fissures, hyperkeratosis or lichenification, and vesicles) with the intensity of pruritus or pain to assess the severity of symptoms. This composite score assigns 0 (mild) to 3 (severe) to each component, giving a maximum disease severity of 21. A separate score is assigned for hands and feet.

    Time frame: Baseline, Week 16

  10. Percentage of Participants with Hand Dermatitis Achieving HECSI-90 Score

    The HECSI scoring system incorporates both the extent and the intensity of the disease. The total sum called the HECSI score will be calculated, varying from 0 to a maximum severity score of 360 points.

    Time frame: Week 16

  11. Percent Change from Baseline in Hand Eczema Severity Index (HECSI) Score for Participants with Hand Dermatitis

    The HECSI scoring system incorporates both the extent and the intensity of the disease. The total sum called the HECSI score will be calculated, varying from 0 to a maximum severity score of 360 points.

    Time frame: Baseline, Week 16

  12. Percentage of Participants with Hand Dermatitis Achieving HECSI-50 Score

    The HECSI scoring system incorporates both the extent and the intensity of the disease. The total sum called the HECSI score will be calculated, varying from 0 to a maximum severity score of 360 points.

    Time frame: Week 16

  13. Percentage of Participants with Hand Dermatitis Achieving HECSI-75 Score

    The HECSI scoring system incorporates both the extent and the intensity of the disease. The total sum called the HECSI score will be calculated, varying from 0 to a maximum severity score of 360 points.

    Time frame: Week 16

  14. Change from Baseline in Quality of Life in Hand Eczema Questionnaire (QOLHEQ) for Participants with Hand Dermatitis

    The QOLHEQ consists of 30 items that can be summarized according to 4 domains of HRQoL: impairments over the last 7 days because of (1) symptoms, (2) emotions, (3) limitations in functioning, or (4) treatment and prevention. The total QOLHEQ score ranges between 0 and 117, with higher scores indicative of a poor HE-specific HRQoL.

    Time frame: Baseline, Week 16

07

Study locations

76 sites
  • First OC Dermatology Research Inc
    Fountain Valley, California 92708, United States
  • Dermatology Research Associates
    Los Angeles, California 90045, United States
  • Encore Medical Research
    Hollywood, Florida 33024, United States
  • Research Associates of South Florida - Miami - Southwest 8th Street
    Miami, Florida 33134, United States
  • Renstar Medical Research
    Ocala, Florida 34470, United States
  • DeNova Research
    Chicago, Illinois 60602, United States
  • Southern Indiana Clinical Trials
    New Albany, Indiana 47150, United States
  • Revival Research Institute, LLC
    Troy, Michigan 48084, United States
  • MediSearch Clinical Trials
    Saint Joseph, Missouri 64506, United States
  • Care Access - Hoboken
    Hoboken, New Jersey 07030, United States
  • Optima Research - Boardman
    Boardman, Ohio 44512, United States
  • Progressive Clinical Research
    San Antonio, Texas 78213, United States
  • Texas Dermatology and Laser Specialists
    San Antonio, Texas 78218, United States
  • Complete Dermatology
    Sugar Land, Texas 77479, United States
  • CONEXA Investigacion Clinica S.A.
    Buenos Aires, 1012, Argentina
  • Investigaciones Medicas Imoba Srl
    Buenos Aires, C1056ABH, Argentina
  • CIPREC
    Buenos Aires, C1061AAS, Argentina
  • Instituto de Neumonologia Y Dermatologia
    Buenos Aires, C1425BEA, Argentina
  • Psoriahue
    Buenos Aires, C1425DKG, Argentina
  • Fundación Respirar
    Buenos Aires, C1426ABP, Argentina
  • Parra Dermatología
    Mendoza, 5500, Argentina
  • Fundacion Estudios Clinicos
    Rosario, 2000, Argentina
  • INECO Neurociencias Oroño
    Rosario, 2000, Argentina
  • Instituto de Investigaciones Clinicas Rosario
    Rosario, S2000CVD, Argentina
  • Centro de Investigaciones San Miguel
    San Miguel, 1663, Argentina
  • The Skin Centre
    Benowa, 4217, Australia
  • Skin Health Institute Inc.
    Carlton, 3053, Australia
  • Cornerstone Dermatology
    Coorparoo, 4151, Australia
  • Fremantle Dermatology
    Fremantle, 6160, Australia
  • St George Dermatology & Skin Cancer Centre
    Kogarah, 2217, Australia
  • Institute for Skin, Health and Immunity
    Mitcham, 3132, Australia
  • Paratus Clinical Research Woden
    Phillip, 2606, Australia
  • Veracity Clinical Research
    Woolloongabba, 4102, Australia
  • SimcoDerm Medical and Surgical Dermatology Center
    Barrie, L4M 7G1, Canada
  • INTERMED Groupe Sante
    Chicoutimi, G7H 7Y8, Canada
  • Interior Dermatology Centre - Probity - PPDS
    Kelowna, V1W 4V5, Canada
  • DermEffects
    London, N6H 5L5, Canada
  • Centre de Recherche Saint-Louis
    Montreal, H1Y 3L1, Canada
  • Centre de Recherche Saint-Louis
    Québec, G1W 4R4, Canada
  • CaRe Clinic
    Red Deer, T4P 1K4, Canada
  • Private Practice - Dr. Rachel Asiniwasis
    Regina, S4V 1R9, Canada
  • FACET Dermatology
    Toronto, M4E 1R7, Canada
  • Wiseman Dermatology Research Inc.
    Winnipeg, R3M 3Z4, Canada
  • Kosugi Dermatology Clinic
    Kawasaki-shi, 211-0063, Japan
  • Maruyama Dermatology Clinic
    Kōtoku, 136-0074, Japan
  • University Hospital,Kyoto Prefectural University of Medicine
    Kyoto, 602-8566, Japan
  • Tanpopo Skin Clinic
    Ōta-ku, 143-0023, Japan
  • Pansy Skin Clinic
    Saitama, 330-0064, Japan
  • Dermatology and Ophthalmology Kume Clinic
    Sakai, 593-8324, Japan
  • Tokyo Medical University Hospital
    Shinjuku-ku, 160-0023, Japan
  • Tachikawa Dermatology Clinic
    Tachikawa, 190-0023, Japan
  • Scientia Investigacion Clinica S.C.
    Chihuahua City, 31203, Mexico
  • Cryptex Investigación Clínica S.A. de C.V.
    Cuauhtémoc, Ciudad de México, 06100, Mexico
  • Kohler & Milstein Research S.A. De C.V.
    Mérida, 97070, Mexico
  • Eukarya Pharmasite S.C.
    Monterrey, 64718, Mexico
  • Arké SMO S.A de C.V
    Veracruz, 91900, Mexico
  • Korea University Ansan Hospital
    Ansan-si, 15355, South Korea
  • The Catholic University of Korea, Incheon St. Mary's Hospital
    Bupyeong-gu, 21431, South Korea
  • Pusan National University Yangsan Hospital
    Busan, 50612, South Korea
  • Chosun University Hospital
    Gwangju, 61453, South Korea
  • Kyungpook National University Hospital
    Junggu, 41944, South Korea
  • Seoul National University Hospital
    Seoul, 03080, South Korea
  • Severance Hospital, Yonsei University Health System
    Seoul, 03722, South Korea
  • Konkuk University Medical Center
    Seoul, 05030, South Korea
  • Kyung Hee University Hospital at Gangdong
    Seoul, 05278, South Korea
  • Asan Medical Center
    Seoul, 05505, South Korea
  • The Catholic Univ. of Korea Seoul St. Mary's Hospital
    Seoul, 06591, South Korea
  • Ajou University Hospital
    Suwon, 16499, South Korea
  • Chang Gung Memorial Hospital at Kaohsiung
    Kaohsiung Niao Sung Dist, 83301, Taiwan
  • New Taipei Municipal TuCheng Hospital
    New Taipei City, 236, Taiwan
  • National Cheng Kung University Hospital
    Tainan, 704, Taiwan
  • National Taiwan University Hospital
    Taipei, 10002, Taiwan
  • Taipei Veterans General Hospital
    Taipei, 11217, Taiwan
  • Tri-Service General Hospital
    Taipei, 114, Taiwan
  • Chang Gung Medical Foundation-Linkou Branch
    Taoyuan, 333, Taiwan
  • National Taiwan University Hospital - Hsinchu branch
    Zhubei, 302, Taiwan
08

References and documents

Related links

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2025 to primary completion in May 2026, 12 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 4, 2025
First posted
Apr 10, 2025
StartActual
Apr 21, 2025
Primary completionActual
May 13, 2026
CompletionActual
Jul 28, 2026
Last update
Aug 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06921759
Responsible party
Sponsor
First posted
Apr 10, 2025
Start date
Apr 21, 2025
Primary completion
May 13, 2026
Completion
Jul 28, 2026
Last update
Aug 20, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lebrikizumab

Start the discussion